Aliases & Classifications for Pancytopenia

MalaCards integrated aliases for Pancytopenia:

Name: Pancytopenia 12 29 55 6 44 15 72

Classifications:



External Ids:

Disease Ontology 12 DOID:12450
ICD9CM 35 284.1
MeSH 44 D010198
ICD10 33 D61.81
UMLS 72 C0030312

Summaries for Pancytopenia

Disease Ontology : 12 An anemia that is characterized by a reduction in the number of red blood cells, white blood cells, and platelets.

MalaCards based summary : Pancytopenia is related to fanconi anemia, complementation group a and amegakaryocytic thrombocytopenia, congenital. An important gene associated with Pancytopenia is DNAJC21 (DnaJ Heat Shock Protein Family (Hsp40) Member C21), and among its related pathways/superpathways are PI3K-Akt signaling pathway and NF-kappaB Signaling. The drugs Prednisone and Oprelvekin have been mentioned in the context of this disorder. Affiliated tissues include bone, bone marrow and t cells, and related phenotypes are homeostasis/metabolism and hematopoietic system

Wikipedia : 75 Pancytopenia is a medical condition in which there is a reduction in the number of red and white blood... more...

Related Diseases for Pancytopenia

Diseases related to Pancytopenia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 713)
# Related Disease Score Top Affiliating Genes
1 fanconi anemia, complementation group a 33.1 THPO IL3 DKC1 DHFR
2 amegakaryocytic thrombocytopenia, congenital 32.3 THPO MPL IL3
3 hypersplenism 31.3 THPO FOXP3 EPO
4 diamond-blackfan anemia 31.2 TP53 THPO MPL IL3 EPO CSF2
5 neutropenia 31.2 TPMT IL3 CSF3 CSF2
6 acquired immunodeficiency syndrome 30.9 TP53 EPO CSF2
7 acute radiation syndrome 30.9 EPO CSF3
8 dyskeratosis congenita 30.9 TP53 TERT DKC1 CSF3 CSF2
9 granulocytopenia 30.8 IL3 CSF3 CSF2
10 myeloma, multiple 30.7 TP53 EPO CSF3 CSF2
11 deficiency anemia 30.6 THPO IL3 EPO CSF3
12 felty syndrome 30.4 IL3 CSF3 CSF2
13 refractory anemia 30.2 MPL IL3 EPO
14 oligodendroglioma 30.1 TP53 TERT MGMT
15 malaria 30.1 TCN2 FOXP3 EPO DHFR CSF3 CSF2
16 aplastic anemia 30.1 TP53 THPO TERT SH2D1A MPL IL3
17 myelofibrosis 30.0 THPO MPL IL3 EPO CSF3
18 cyclic neutropenia 29.9 IL3 CSF3 CSF2
19 central nervous system lymphoma 29.9 TP53 TCN2 MGMT
20 lymphoma, non-hodgkin, familial 29.7 TP53 SH2D1A IL3 CSF3 CSF2
21 severe congenital neutropenia 29.7 IL3 CSF3 CSF2
22 polycythemia 29.5 THPO MPL IL3 EPO
23 thrombocytosis 29.4 THPO MPL IL3 EPO CSF2
24 polycythemia vera 29.4 THPO MPL IL3 EPO
25 leukemia, acute myeloid 29.1 TP53 THPO TERT SAMD9L MPL IL3
26 myelodysplastic syndrome 29.1 TP53 THPO TERT SAMD9L MPL IL3
27 leukemia, chronic myeloid 29.0 THPO MPL IL3 EPO CSF3 CSF2
28 hematologic cancer 28.3 TP53 THPO MPL IL3 CSF3 CSF2
29 ataxia-pancytopenia syndrome 12.7
30 samd9l-related ataxia-pancytopenia syndrome 12.3
31 pancytopenia and occlusive vascular disease 12.2
32 hoyeraal hreidarsson syndrome 12.0
33 dyskeratosis congenita, x-linked 11.6
34 sackey sakati aur syndrome 11.6
35 langerhans cell histiocytosis 11.5
36 evans' syndrome 11.5
37 immunodeficiency, common variable, 13 11.5
38 fanconi anemia, complementation group c 11.5
39 fanconi anemia, complementation group d2 11.5
40 fanconi anemia, complementation group b 11.5
41 hemophagocytic lymphohistiocytosis 11.4
42 wt limb-blood syndrome 11.4
43 fanconi-like syndrome 11.4
44 lymphoproliferative syndrome, x-linked, 2 11.4
45 lymphoproliferative syndrome, x-linked, 1 11.4
46 griscelli syndrome 11.4
47 acute myeloblastic leukemia with maturation 11.4
48 radioulnar synostosis with amegakaryocytic thrombocytopenia 2 11.2
49 bone marrow failure syndrome 3 11.2
50 cerebroretinal microangiopathy with calcifications and cysts 2 11.2

Graphical network of the top 20 diseases related to Pancytopenia:



Diseases related to Pancytopenia

Symptoms & Phenotypes for Pancytopenia

MGI Mouse Phenotypes related to Pancytopenia:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.27 CPT2 CSF1 CSF2 DHFR DKC1 EPO
2 hematopoietic system MP:0005397 10.25 CSF1 CSF2 CSF3 DHFR DKC1 EPO
3 immune system MP:0005387 10.17 CPT2 CSF1 CSF2 CSF3 DHFR DKC1
4 mortality/aging MP:0010768 10 CPT2 CSF1 CSF2 DHFR DKC1 DNAJC21
5 integument MP:0010771 9.91 CSF1 CSF2 CSF3 DHFR DKC1 EPO
6 neoplasm MP:0002006 9.43 CSF2 DKC1 MGMT SAMD9L TERT TP53
7 respiratory system MP:0005388 9.28 CPT2 CSF1 CSF2 DKC1 EPO FOXP3

Drugs & Therapeutics for Pancytopenia

Drugs for Pancytopenia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 139)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
2
Oprelvekin Approved, Investigational Phase 4 145941-26-0
3 Antilymphocyte Serum Phase 4
4
Nandrolone phenpropionate Approved, Illicit, Investigational Phase 3 62-90-8 229455
5
Nandrolone decanoate Approved, Illicit Phase 3 360-70-3 9677
6
Miconazole Approved, Investigational, Vet_approved Phase 2, Phase 3 22916-47-8 4189
7
Vidarabine Approved, Investigational Phase 2, Phase 3 24356-66-9 21704 32326
8
Nandrolone Experimental, Investigational Phase 3 434-22-0 9904
9 Thymoglobulin Phase 3
10 Hormone Antagonists Phase 3
11 Hormones Phase 3
12 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 3
13 Androgens Phase 3
14 Anabolic Agents Phase 3
15 Immunosuppressive Agents Phase 2, Phase 3
16 Antirheumatic Agents Phase 2, Phase 3
17 Cyclosporins Phase 2, Phase 3
18 Anti-Infective Agents Phase 2, Phase 3
19 Antifungal Agents Phase 2, Phase 3
20 Calcineurin Inhibitors Phase 2, Phase 3
21 Alkylating Agents Phase 2, Phase 3
22 Antineoplastic Agents, Alkylating Phase 2, Phase 3
23
Dexamethasone Approved, Investigational, Vet_approved Phase 2 50-02-2 5743
24
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 2 1177-87-3
25
Doxorubicin Approved, Investigational Phase 2 23214-92-8 31703
26
Prednisolone phosphate Approved, Vet_approved Phase 2 302-25-0
27
Methylprednisolone hemisuccinate Approved Phase 2 2921-57-5
28
Methylprednisolone Approved, Vet_approved Phase 2 83-43-2 6741
29
Prednisolone Approved, Vet_approved Phase 2 50-24-8 5755
30
Idarubicin Approved Phase 2 58957-92-9 42890
31
Cytarabine Approved, Experimental, Investigational Phase 2 147-94-4, 65-46-3 6253
32
Danazol Approved Phase 1, Phase 2 17230-88-5 28417
33
Busulfan Approved, Investigational Phase 1, Phase 2 55-98-1 2478
34
Tacrolimus Approved, Investigational Phase 2 104987-11-3 445643 439492 6473866
35
Mycophenolic acid Approved Phase 2 24280-93-1 446541
36
Abatacept Approved Phase 1, Phase 2 332348-12-6 10237
37
Hydroxyurea Approved Phase 1, Phase 2 127-07-1 3657
38
Melphalan Approved Phase 1, Phase 2 148-82-3 460612 4053
39
Mesna Approved, Investigational Phase 2 3375-50-6 598
40
rituximab Approved Phase 1, Phase 2 174722-31-7 10201696
41
alemtuzumab Approved, Investigational Phase 2 216503-57-0
42
tannic acid Approved Phase 2 1401-55-4
43
Benzocaine Approved, Investigational Phase 2 94-09-7, 1994-09-7 2337
44
Sirolimus Approved, Investigational Phase 1, Phase 2 53123-88-9 6436030 5284616 46835353
45
Everolimus Approved Phase 1, Phase 2 159351-69-6 6442177 70789204
46
Lenalidomide Approved Phase 1, Phase 2 191732-72-6 216326
47
Sargramostim Approved, Investigational Phase 2 83869-56-1, 123774-72-1
48
Lenograstim Approved, Investigational Phase 2 135968-09-1
49
Thiotepa Approved, Investigational Phase 2 52-24-4 5453
50
Tegafur Approved, Investigational Phase 2 17902-23-7 5386

Interventional clinical trials:

(show top 50) (show all 117)
# Name Status NCT ID Phase Drugs
1 Different Doses of Anti-thymocyte Globin With 2.5 or 3.75mg/kg to Treat Child Severe Aplastic Anemia Unknown status NCT01997372 Phase 4 ATG
2 Effect of Treatment Using rhIL-11 in Patients With Thrombocytopenia After Chemotherapy for Childhood Acute Lymphoblastic Leukemia Completed NCT02314273 Phase 4 rhIL-11
3 Randomized Clinical Trial of the Use of Eltrombopag in Children With Idiopathic Aplastic Anemia Recruiting NCT03243656 Phase 4 Eltrombopag
4 Risk-Adapted Allogeneic Stem Cell Transplantation For Mixed Donor Chimerism In Patients With Selected Non-Malignant Diseases Unknown status NCT01019876 Phase 2, Phase 3 Fludarabine;Cyclophosphamide;Cyclophosphamide 40;Cyclophosphamide 30
5 The Impact of Red Cell Age on Product Utilization in the Chronically Transfused Outpatient Population Unknown status NCT02393508 Phase 3
6 Multi-Center Trial of Anti-Thymocyte Globulin in Treatment of Aplastic Anemia and Other Hematologic Disorders Completed NCT00000597 Phase 3 antilymphocyte serum;nandrolone
7 Bone Marrow Transplantation for Non-Malignant Congenital Bone Marrow Failure Disorders Completed NCT00176878 Phase 2, Phase 3 Fludarabine monophosphate;Busulfan
8 Randomized Comparison of Cyclophosphamide Versus Cyclophosphamide Plus Fludarabine In Addition To Anti-Thymocyte Globulin for the Conditioning Therapy in Allogeneic Hematopoietic Cell Transplantation for Bone Marrow Failure Syndrome Completed NCT00774527 Phase 3 Cyclophosphamide-fludarabine-anti thymocyte globulin
9 Outcome of Peripheral Blood Allogenic Stem Cell Transplantation Using Non-anti Thymocyte Globulin (ATG ) Conditioning Regimens in Severe Aplastic Anemia Patients Not yet recruiting NCT03295058 Phase 2, Phase 3 Non ATG Conditioning regimen;GVHD Prophylaxis;ATG conditioning regimen
10 Phase II Study of the Levamisole Combined With Cyclosporine A in Patients With Subclinical Paroxysmal Nocturnal Hemoglobinuria and PNH in the Setting of Another Bone Marrow Failure Syndromes(PNH-2013) Unknown status NCT01760096 Phase 2 Levamisole+cyclosporin A+Glucocorticoids;cyclosporin A+Glucocorticoids;Glucocorticoids
11 Phase II Study of the Levamisole Combined With Cyclosporine A in Patients With Classic Paroxysmal Nocturnal Hemoglobinuria Unknown status NCT01642979 Phase 2 Levamisole+cyclosporin A+Glucocorticoids;cyclosporin A+Glucocorticoids;Glucocorticoids
12 A Single-Arm Phase 2 Study With Optimized Standard Protocol for Severe Aplastic Anemia Unknown status NCT02203396 Phase 2 rabbit ATG, Cyclosporine, Levamisole
13 Using Daily Self-administered Indirect Moxibustion to Zusanli St-36 to Reduce Chemotherapy Induced Pancytopenia: a Feasibility Study Unknown status NCT02781155 Phase 1, Phase 2
14 PhaseⅠ/ⅡTrial of Bone Marrow Derived Mesenchymal Stem Cell Transplantation From Related Donor to Patients With Relapsed/Refractory Aplastic Anemia. Unknown status NCT01305694 Phase 1, Phase 2
15 Male Hormones for Telomere Related Diseases Unknown status NCT02055456 Phase 1, Phase 2 Nandrolone Decanoate
16 Eltrombopag for Enhancing Platelet Engraftment in Adult Patients Undergoing Cord Blood Transplantation Unknown status NCT01757145 Phase 2 Eltrombopag
17 PhaseⅡTrial of Co-transplantation With Bone Marrow Derived Mesenchymal Stem Cells From Related Donors in Alternative Donor Transplantation of Severe Aplastic Anemia. Unknown status NCT02247973 Phase 2
18 A Randomized Trial of Immunosuppression in Aplastic Anemia Patients With Refractory Pancytopenia or Suboptimal Hematologic Response After h-ATG/CsA Treatment Completed NCT00065260 Phase 2 Campath-1H;r-ATG;CsA
19 A Randomized Study of Three Immunosuppressive Regimens in Treatment Naive Patients With Severe Aplastic Anemia: Horse ATG/CsA Taper vs Rabbit-ATG/CsA vs Alemtuzumab Completed NCT00260689 Phase 2 Cyclosporine;Alemtuzumab
20 Doxil® (Pegylated Liposomal Doxorubicin), Dexamethasone Plus Thalidomide (Ddt) in Previously Untreated Multiple Myeloma: A Study Evaluating Efficacy, Toxicity, Harvest Yield and Quality of Life Completed NCT00222105 Phase 2 Doxil;Thalidomide;Dexamethasone
21 Phase I/II Study of Reduced Intensity Conditioning for Patients With Non-Malignant Diseases Using CD3+/CD19+ Depleted Unrelated Donor or Partially Matched Related Donor Peripheral Stem Cells Completed NCT02277639 Phase 2
22 A Randomized Trial of a Novel Immunosuppressive Combination of ATG, CsA and Sirolimus (Rapamune) vs a Slow Taper Cyclosporine Regimen in Subjects With Severe Aplastic Anemia Completed NCT00061360 Phase 2 ATG+Rapamune+cyclosporine;ATG+cyclosporine
23 Cyclophosphamide Plus Cyclosporine in Treatment-Naive Severe Aplastic Anemia Completed NCT01193283 Phase 1, Phase 2 Cyclophosphamide;Cyclosporine
24 HLA-HAPLOIDENTICAL FAMILIAL DONOR HEMATOPOIETIC CELL TRANSPLANTATION AFTER REDUCED INTENSITY CONDITIONING OF BUSULFAN, FLUDARABINE, AND ANTI-THYMOCYTE GLOBULIN FOR PATIENTS WITH BONE MARROW FAILURE SYNDROME - A PHASE 2 STUDY Completed NCT00731328 Phase 2
25 A Non-randomized, Open-label, Phase II Study to Assess the Safety and Efficacy of Eltrombopag in Japanese Subjects With Refractory, Moderate or More Severe Aplastic Anemia Completed NCT02148133 Phase 2 Eltrombopag 12.5 mg;Eltrombopag 25 mg
26 A Non-randomized, Phase II Study of Eltrombopag in Combination With Rabbit Anti-thymocyte Globulin/Cyclosporine A (ATG/CsA) in Subjects With Moderate or More Severe Aplastic Anemia Who Have Not Received Prior ATG/Anti-lymphocyte Globulin (ALG)-Based Immunosuppressive Therapy Completed NCT02404025 Phase 2 Eltrombopag;Rabbit ATG;CsA
27 Transfusion of CD45RA-depleted Donor Lymphocytes to Improve Regeneration of Antimicrobial Immunity After TCR-alpha/Beta Depleted Hematopoietic Stem Cell Transplantation Completed NCT02337595 Phase 1, Phase 2
28 Allogeneic Mixed Chimerism Stem Cell Transplantation Utilizing In Vivo and In Vitro Campath for Hemoglobinopathies and Bone Marrow Failure Syndromes Completed NCT00004143 Phase 2 Campath, Chemo and/or TBI Allo SCT
29 A Multicenter Phase I/II Dose Escalation Study of Lenalidomide in Relapse/Refractory Waldenstrom Macroglobulinemia Completed NCT02302469 Phase 1, Phase 2 Revlimid
30 CD34+Stem Cell Selection for Patients Receiving Partially Matched Family or Matched Unrelated Adult Donor Allogeneic Stem Cell Transplantations for Malignant and Non-Malignant Disease Completed NCT01049854 Phase 2 Full Intensity with TBI;Full Intensity;Reduced Intensity;Reduced Intensity (Fanconi)
31 Idarubicin and Ara-C in Combination With Gemtuzumab-Ozogamicin (IAGO) for Young Untreated Patients, Without an HLA Identical Sibling, With High Risk MDS or AML Developing After a Preceding Period With MDS During 6 Months Duration: A Phase II Study Completed NCT00077116 Phase 2 busulfan;cyclophosphamide;cytarabine;gemtuzumab ozogamicin;idarubicin
32 A Pilot Study of Fludarabine Plus Cyclophosphamide in Refractory Severe Aplastic Anemia Completed NCT01187017 Phase 1, Phase 2 Cyclophosphamide;Fludarabine
33 Male Hormones for Telomere Related Diseases Completed NCT01441037 Phase 1, Phase 2 Danazol
34 A Pilot Study of Alemtuzumab (Campath[R]) in Patients With Myelodysplastic Syndrome (MDS) Completed NCT00217594 Phase 2 Alemtuzumab (Campath)
35 A Randomized Trial of Recombinant Humanized Anti-IL-2 Receptor Antibody (Daclizumab) Versus Antithymocyte Globulin (ATG) to Treat the Cytopenia of Myelodysplastic Syndrome (MDS) Completed NCT00072969 Phase 2 Daclizumab
36 A Randomized Trial for the Treatment of Relapsing Aplastic Anemia With Mycophenolate Mofetil (MMF) and Cyclosporine (CSA) Completed NCT00005935 Phase 2 Mycophenolate mofetil;Cyclosporine
37 Horse ATG/CsA in Aplastic Anemia Patients Unresponsive to or With a Suboptimal Response to Rabbit ATG/CsA Treatment Completed NCT00944749 Phase 2 h-ATG (ATGAM );Cyclosporine (Gengraf )
38 AMD3100 in Combination With G-CSF to Mobilize Peripheral Blood Stem Cells in Patients With Fanconi Anemia(FA): A Phase I/II Study Completed NCT00479115 Phase 1, Phase 2 AMD3100
39 Fludarabine-based Conditioning for Allogeneic Marrow Transplantation From HLA-compatible Unrelated Donors in Severe Aplastic Anemia (BMT CTN #0301) Completed NCT00326417 Phase 1, Phase 2 Fludarabine;Cyclophosphamide 150mg;Cyclophosphamide 100mg;Cyclophosphamide 50mg
40 A Phase II Trial of Non-Myeloablative (NMA) Conditioning and Transplantation of Partially HLA-Mismatched/Haploidentical Related or Matched Unrelated Donor (MUD) Bone Marrow for Newly Diagnosed Patients With Severe Aplastic Anemia Recruiting NCT02833805 Phase 2 Thymoglobulin;Fludarabine;Cyclophosphamide;Tacrolimus;Mycophenolate mofetil
41 A UK Multicentre Study of Haploidentical Stem Cell Transplantation in Patients With Haematological Malignancies Recruiting NCT01597219 Phase 2
42 A Study of T-Cell Replete, HLA-Mismatched Haploidentical Bone Marrow Transplantation With Post-Transplant Cyclophosphamide for Patients With Severe Aplastic Anemia Lacking HLA-Matched Related Donor Recruiting NCT02828592 Phase 2 Fludarabine;Cyclophosphamide;Rabbit ATG;Cyclophosphamide
43 A Phase I/II Trial of Reduced Intensity Conditioning and Familial HLA-Mismatched Bone Marrow Transplantation in Children With Non-Malignant Disorders Recruiting NCT03128996 Phase 1, Phase 2 RIC regimen;GVHD prophylaxis regimen
44 Myeloablative Allogeneic Hematopoietic Cell Transplantation Using a Related or Unrelated Donor for the Treatment of Hematological Diseases Recruiting NCT03314974 Phase 2
45 A Phase II Trial of Non-Myeloablative Conditioning and Transplantation of Partially HLA-Mismatched/Haploidentical Related or Matched Unrelated Bone Marrow for Patients With Refractory Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Recruiting NCT02224872 Phase 2 Thymoglobulin;Fludarabine;Cyclophosphamide;Mesna;Tacrolimus;Mycophenolic acid mofetil
46 Clinical Phase II Trial to Compare Treosulfan-based Conditioning Therapy With Busulfan-based Conditioning Prior to Allogeneic Haematopoietic Stem Cell Transplantation (HSCT) in Paediatric Patients With Non-malignant Diseases Recruiting NCT02349906 Phase 2 Treosulfan;Busilvex
47 Anti-Viral Central Memory CD8 Veto Cells in Haploidentical Hematopoietic Stem Cell Transplantation Recruiting NCT03622788 Phase 1, Phase 2 Cyclophosphamide;Fludarabine
48 PEDS024, Phase I/II Feasibility Study of Busulfan Fludarabine and Thiotepa Conditioning Regimen for Allogeneic Hematopoietic Stem-Cell Transplantation (HSCT) for Children With Non-Malignant Disorders Recruiting NCT03513328 Phase 1, Phase 2 Thiotepa--single daily dose;Thiotepa--escalated dose
49 Lung Transplant in Tandem With Bone Marrow Transplant for Combined Lung and Bone Marrow Failure Recruiting NCT03500731 Phase 1, Phase 2 Rituximab;Alemtuzumab;Fludarabine;Thiotepa;G-CSF;Hydroxyurea
50 Transplantation of Umbilical Cord Blood for Patients With Hematological Diseases With Cyclophosphamide/Fludarabine/Total Body Irradiation or Cyclophosphamide/Fludarabine/Thiotepa/Total Body Irradiation Myeloablative Preparative Regimen Recruiting NCT00719888 Phase 2 Cyclophosphamide;Cyclosporine;Fludarabine;Mycophenolate Mofetil;Thiotepa

Search NIH Clinical Center for Pancytopenia

Cochrane evidence based reviews: pancytopenia

Genetic Tests for Pancytopenia

Genetic tests related to Pancytopenia:

# Genetic test Affiliating Genes
1 Pancytopenia 29

Anatomical Context for Pancytopenia

MalaCards organs/tissues related to Pancytopenia:

41
Bone, Bone Marrow, T Cells, Myeloid, Liver, B Cells, Lung

Publications for Pancytopenia

Articles related to Pancytopenia:

(show top 50) (show all 6671)
# Title Authors PMID Year
1
Perioperative management for a patient with chronic pancytopenia: a case of aplastic anemia with persistent neutropenia following preoperative administration of G-CSF. 9 38
20094735 2010
2
[Intravascular large B-cell lymphoma with pontine involvement successfully treated with R-hyper-CVAD/R-MTX-Ara-C regimen]. 9 38
20379108 2010
3
Massive ascites associated with all-trans retinoic acid treatment in therapy-related acute promyelocytic leukemia. 9 38
20190483 2010
4
Development of thrombopoietin receptor agonists for clinical use. 9 38
19630808 2009
5
Prolonged and severe thrombocytopenia with pancytopenia induced by radiation-combined temozolomide therapy in a patient with newly diagnosed glioblastoma--analysis of O6-methylguanine-DNA methyltransferase status. 9 38
19037596 2009
6
Reduction of disease activity and disability with high-dose cyclophosphamide in patients with aggressive multiple sclerosis. 9 38
18541787 2008
7
Paradoxical elevated thiopurine S-methyltransferase activity after pancytopenia during azathioprine therapy: potential influence of red blood cell age. 9 38
18520612 2008
8
Acute colchicine intoxication in a child: a case report. 9 38
17505274 2007
9
[Asian variant of intravascular large B-cell lymphoma diagnosed by bone marrow biopsy]. 9 38
17313078 2007
10
Donor-type myelodysplastic syndrome with t(2;3) and monosomy 7 after allogeneic peripheral blood stem cell transplantation and liver transplantation in a patient with severe-type aplastic anemia. 9 38
17118765 2006
11
Two cases of thiopurine methyltransferase (TPMT) deficiency--a lucky save and a near miss with azathioprine. 9 38
16995868 2006
12
MPL mutations in 23 patients suffering from congenital amegakaryocytic thrombocytopenia: the type of mutation predicts the course of the disease. 9 38
16470591 2006
13
Thrombopoietin regulates differentiation of rhesus monkey embryonic stem cells to hematopoietic cells. 9 38
15958695 2005
14
[CD5- CD11c+ CD23- small lymphocytic lymphoma evolving from aplastic anemia]. 9 38
15387287 2004
15
[Spontaneous recovery from pancytopenia in a young female patient with paroxysmal nocturnal hemoglobinuria(PNH): changes in the GPI-anchor expression on peripheral blood cells]. 9 38
15103939 2004
16
Refractory chronic GVHD emerging after splenectomy in a marrow transplant recipient with accelerated phase CML. 9 38
12858207 2003
17
Co-administration of Flt-3 ligand counteracts the actions of thrombopoietin in myelosuppressed rhesus monkeys. 9 38
12694260 2003
18
Safe treatment of thiopurine S-methyltransferase deficient Crohn's disease patients with azathioprine. 9 38
12477776 2003
19
Adult purpura fulminans associated with staphylococcal infection and administration of colony-stimulating factors. 9 38
12609794 2003
20
Severe pancytopenia from thiopurine methyltransferase deficiency: a preventable complication of 6-mercaptopurine therapy in children with Crohn disease. 9 38
12454589 2002
21
Azathioprine therapy and adverse drug reactions in patients with inflammatory bowel disease: impact of thiopurine S-methyltransferase polymorphism. 9 38
12172211 2002
22
Girl with combined cellular immunodeficiency, pancytopenia, malformations, deletion 11q23.3 --> qter, and trisomy 8q24.3 --> qter. 9 38
11920839 2002
23
Development of pancytopenia with neutralizing antibodies to thrombopoietin after multicycle chemotherapy supported by megakaryocyte growth and development factor. 9 38
11895799 2002
24
[Successful combined therapy with ATG, cyclosporin and G-CSF for both liver dysfunction and bone marrow failure in hepatitis-associated aplastic anemia]. 9 38
11680980 2001
25
Colchicine induced toxicity and pancytopenia at usual doses and treatment with granulocyte colony-stimulating factor. 9 38
11361215 2001
26
Early onset methotrexate-induced pancytopenia and response to G-CSF: a report of two cases. 9 38
17039083 2001
27
c-mpl mutations are the cause of congenital amegakaryocytic thrombocytopenia. 9 38
11133753 2001
28
One novel and two recurrent missense DKC1 mutations in patients with dyskeratosis congenita (DKC). 9 38
11491307 2001
29
Severe 6-thioguanine-induced marrow aplasia in a child with acute lymphoblastic leukemia and inherited thiopurine methyltransferase deficiency. 9 38
11037857 2000
30
[Two cases of intravascular lymphomatosis diagnosed antemortem by transbronchial lung biopsy]. 9 38
10723949 2000
31
Serum thrombopoietin levels in thrombocytopenic and non-thrombocytopenic patients with human immunodeficiency virus (HIV-1) infection. 9 38
10530413 1999
32
Successful cytokine treatment of aplastic anemia following living-related orthotopic liver transplantation for non-A, non-B, non-C hepatitis. 9 38
10081639 1999
33
Recurrent hepatosplenomegaly and peripheral blood cytopenia, persistent Epstein-Barr virus infection and central nervous system manifestation in a patient with lymphadenopathy and low serum uric acid. 9 38
9745782 1998
34
Successful treatment of aplastic anemia with G-CSF and high dose erythropoietin. 9 38
9669693 1998
35
Type 1 Gaucher disease: phenotypic expression and natural history in Japanese patients. 9 38
9541479 1998
36
T cell-depleted granulocyte colony-stimulating factor (G-CSF) modified allogenic bone marrow transplantation for hematological malignancy improves graft CD34+ cell content but is associated with delayed pancytopenia. 9 38
9535034 1998
37
Crescentic glomerulonephritis accompanied by myeloperoxidase-antineutrophil cytoplasmic antibodies in a patient having myelodysplastic syndrome with trisomy 7. 9 38
9469507 1998
38
Simultaneous administration of TPO and G-CSF after cytoreductive treatment of rhesus monkeys prevents thrombocytopenia, accelerates platelet and red cell reconstitution, alleviates neutropenia, and promotes the recovery of immature bone marrow cells. 9 38
9293906 1997
39
Growth factor administration following autologous peripheral blood progenitor cell transplantation. 9 38
9373197 1997
40
Prevention of thrombocytopenia by thrombopoietin in myelosuppressed rhesus monkeys accompanied by prominent erythropoietic stimulation and iron depletion. 9 38
9207438 1997
41
Copper deficiency with pancytopenia due to enteral nutrition through jejunostomy. 9 38
16844585 1997
42
Treatment of refractory large granular lymphocytic leukemia with 2-chlorodeoxyadenosine. 9 38
9092691 1997
43
Granulocyte-colony stimulating factor in the treatment of colchicine poisoning. 9 38
9154449 1997
44
[Allopurinol induced pancytopenia in a patient with myeloproliferative disorder]. 9 38
9028164 1997
45
Peripheral blood and bone marrow changes after treatment with ATRA and G-CSF in AML, APL and blast crisis following Vaquez's disease. 9 38
8767533 1996
46
Combination therapy with recombinant human erythropoietin, interferon-alpha-2b and granulocyte-macrophage colony-stimulating factor in idiopathic myelofibrosis. 9 38
8701705 1996
47
Increasing DNA repair methyltransferase levels via bone marrow stem cell transduction rescues mice from the toxic effects of 1,3-bis(2-chloroethyl)-1-nitrosourea, a chemotherapeutic alkylating agent. 9 38
8552605 1996
48
[The Recormon (recombinant erythropoietin) treatment of a patient with pancytopenia of the blood and chronic viral hepatitis C]. 9 38
9019832 1996
49
Early recovery of host-derived hematopoiesis in marrow transplant recipients conditioned with high-dose busulfan and cyclophosphamide. 9 38
7670408 1995
50
Trilineage response to granulocyte colony-stimulating factor administration in a patient with myelodysplastic syndrome. 9 38
7545637 1995

Variations for Pancytopenia

ClinVar genetic disease variations for Pancytopenia:

6
# Gene Variation Type Significance SNP ID GRCh37 Pos GRCh38 Pos
1 FOXP3 NM_014009.3(FOXP3): c.1190G> A (p.Arg397Gln) single nucleotide variant Pathogenic rs1057520529 X:49107901-49107901 X:49251440-49251440
2 CPT2 NM_000098.3(CPT2): c.149C> A (p.Pro50His) single nucleotide variant Pathogenic rs28936375 1:53662764-53662764 1:53197092-53197092
3 TTR NM_000371.3(TTR): c.424G> A (p.Val142Ile) single nucleotide variant Pathogenic rs76992529 18:29178618-29178618 18:31598655-31598655
4 DNAJC21 NM_001012339.3(DNAJC21): c.544C> T (p.Arg182Ter) single nucleotide variant Pathogenic 5:34937536-34937536 5:34937431-34937431
5 TP53 NM_000546.5(TP53): c.742C> T (p.Arg248Trp) single nucleotide variant Pathogenic rs121912651 17:7577539-7577539 17:7674221-7674221
6 SOX3 NM_005634.2(SOX3): c.735_737dup (p.Ala248dup) duplication Uncertain significance rs398124211 X:139586489-139586491 X:140504324-140504326

Expression for Pancytopenia

Search GEO for disease gene expression data for Pancytopenia.

Pathways for Pancytopenia

Pathways related to Pancytopenia according to GeneCards Suite gene sharing:

(show all 19)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.77 TP53 TERT IL3 EPO CSF3 CSF1
2 12.4 SH2D1A MPL IL3 FOXP3
3
Show member pathways
12.16 THPO MPL IL3 EPO CSF3 CSF2
4
Show member pathways
12.15 TP53 TCN2 DHFR CSF1
5
Show member pathways
11.98 TP53 THPO TERT IL3 DKC1
6 11.73 TTR THPO MPL
7
Show member pathways
11.69 FOXP3 CSF3 CSF2
8
Show member pathways
11.58 IL3 FOXP3 CSF2
9 11.47 TERT CSF3 CSF2
10 11.42 THPO IL3 EPO CSF3 CSF2 CSF1
11 11.3 CSF3 CSF2 CSF1
12 11.26 IL3 EPO CSF1
13 11.23 IL3 EPO CSF3 CSF2 CSF1
14 11.23 THPO MPL IL3 EPO CSF3 CSF2
15 11.11 TTR THPO MPL
16 11.02 IL3 CSF3 CSF2 CSF1
17 11.01 IL3 CSF3 CSF2 CSF1
18 10.86 THPO IL3 CSF3 CSF2 CSF1
19 10.65 CSF2 CSF1

GO Terms for Pancytopenia

Cellular components related to Pancytopenia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.23 TTR THPO TCN2 IL3 EPO CSF3

Biological processes related to Pancytopenia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 positive regulation of cell proliferation GO:0008284 9.63 THPO IL3 EPO CSF3 CSF2 CSF1
2 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.54 TP53 IL3 CSF3
3 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.5 IL3 EPO CSF2
4 positive regulation of macrophage derived foam cell differentiation GO:0010744 9.43 CSF2 CSF1
5 replicative senescence GO:0090399 9.4 TP53 TERT
6 thrombopoietin-mediated signaling pathway GO:0038163 9.26 THPO MPL
7 cell proliferation GO:0008283 9.26 TP53 THPO EPO CSF1
8 cytokine-mediated signaling pathway GO:0019221 9.1 TP53 MPL IL3 CSF3 CSF2 CSF1

Molecular functions related to Pancytopenia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 hormone activity GO:0005179 9.43 TTR THPO EPO
2 growth factor activity GO:0008083 9.35 THPO IL3 CSF3 CSF2 CSF1
3 telomerase activity GO:0003720 9.16 TERT DKC1
4 cytokine activity GO:0005125 9.1 THPO IL3 EPO CSF3 CSF2 CSF1

Sources for Pancytopenia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....